Reuters logo
BRIEF-Biogen enters into exclusive, worldwide license agreement for Factor IX
January 5, 2017 / 10:55 PM / 8 months ago

BRIEF-Biogen enters into exclusive, worldwide license agreement for Factor IX

Jan 5 (Reuters) - Biogen Inc

* Biogen exercises option to enter into exclusive, worldwide license agreement for Factor IX utilizing Amunix’ Xten half-life extension technology

* Amunix Operating Inc - to get upfront $1.25 million payment, will also be eligible to receive up to $17.25 million in clinical and commercial milestone payments Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below